We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First AI-Powered Blood Test Identifies Patients in Earliest Stage of Breast Cancer

By LabMedica International staff writers
Posted on 16 Dec 2024

Standard breast cancer tests typically include a physical exam, X-ray or ultrasound scans, and a biopsy to analyze tissue samples. More...

Current early detection strategies often rely on screening based on age or risk factors. Now, a new method promises to enhance early detection and monitoring of breast cancer, potentially leading to a screening test for multiple types of cancer.

Developed by researchers at The University of Edinburgh (Scotland, UK), the new screening method combines laser analysis with artificial intelligence (AI). This innovative approach is the first to detect breast cancer at its earliest stage, known as stage 1a, which is undetectable with current tests. The method uses Raman spectroscopy, a laser analysis technique, paired with machine learning, a form of AI. While similar techniques have been trialed for other cancers, they could only detect disease starting at stage two. The process involves shining a laser into blood plasma from patients, and then analyzing how the light interacts with the blood using a spectrometer. This reveals minute changes in the chemical composition of cells and tissues, which serve as early disease indicators. A machine learning algorithm then interprets the data, identifying patterns and classifying the samples.

In a pilot study with 12 breast cancer patient samples and 12 healthy control samples, the technique identified breast cancer at stage 1a with 98% accuracy. The study, published in Journal of Biophotonics, also demonstrated the method’s ability to distinguish between the four main subtypes of breast cancer with over 90% accuracy. This could enable more personalized and effective treatments. The researchers believe that implementing this as a screening tool could identify more patients at the earliest stages of breast cancer, improving treatment success. They plan to expand the study to include more participants and test early detection for other types of cancer.

“Most deaths from cancer occur following a late-stage diagnosis after symptoms become apparent, so a future screening test for multiple cancer types could find these at a stage where they can be far more easily treated,” said Dr. Andy Downes, of the University of Edinburgh’s School of Engineering, who led the study. “Early diagnosis is key to long-term survival, and we finally have the technology required. We just need to apply it to other cancer types and build up a database, before this can be used as a multi-cancer test.”


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.